AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16009798 — intervention group
Group type: COMPARATOR
Intervention: Sham nasal continuous positive airway pressure (nCPAP) for 12 weeks
Number of subjects: 27
Study 12575879 — intervention group
Group type: EXPERIMENTAL
Intervention: HAMMER (hierarchical attribute matching mechanism for elastic registration)
Number of subjects: 0
Study 12575879 — intervention group
Group type: EXPERIMENTAL
Intervention: HAMMER
Number of subjects: 0
Study 11864448 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamins E (280 mg), C (100 mg), and beta-carotene (25 mg) daily for 20 weeks
Number of subjects: 100
Study 11864448 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamins E, C, and beta-carotene
Number of subjects: 100
Study 7758899 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 aPTT units LMWH (Mono‐Embolex)
Number of subjects: 59
Study 7758899 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 I.U. UFH
Number of subjects: 59
Study 7758899 — intervention group
Group type: COMPARATOR
Intervention: No injection
Number of subjects: 59
Study 2207852 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanguinaria toothpaste and oral rinse regimen
Number of subjects: 260
Study 7218971 — intervention group
Group type: EXPERIMENTAL
Intervention: Inversion
Number of subjects: 440
Study 7218971 — intervention group
Group type: COMPARATOR
Intervention: Amputation
Number of subjects: 440
Study 30849011 — intervention group
Group type: EXPERIMENTAL
Intervention: In-office tooth bleaching with 35% hydrogen peroxide for 45 minutes followed by at-home bleaching with 10% carbamide peroxide for 1 hour/day until satisfactory color is obtained.
Number of subjects: 26
Study 30849011 — intervention group
Group type: COMPARATOR
Intervention: At-home bleaching with 10% carbamide peroxide for 1 hour/day until satisfactory color is obtained.
Number of subjects: 26
Study 30849011 — intervention group
Group type: EXPERIMENTAL
Intervention: In-office tooth bleaching with 35% hydrogen peroxide followed by at-home bleaching.
Number of subjects: 26
Study 28735818 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuminoids (1000mg/day plus piperine 10mg/day)
Number of subjects: 118
Study 28735818 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus standard of care
Number of subjects: 118
Study 25236187 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion axillary lymph node dissection (ALND)
Number of subjects: 180
Study 25236187 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative sentinel lymph node (SLN) analysis
Number of subjects: 180
Study 25236187 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracapsular extension
Number of subjects: 180
Study 25236187 — intervention group
Group type: EXPERIMENTAL
Intervention: Reoperative surgery
Number of subjects: 180
Study 25236187 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative SLN analysis
Number of subjects: 180
Study 23736369 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral-risk information plus personal FHH-based risk assessment (BRI+FHH)
Number of subjects: 221
Study 23736369 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral-risk information (BRI)
Number of subjects: 221
Study 23736369 — intervention group
Group type: COMPARATOR
Intervention: Food safety control (Control)
Number of subjects: 221
Study 21257114 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-based intervention (n = 133)
Number of subjects: 264
Study 21257114 — intervention group
Group type: COMPARATOR
Intervention: Standard care control condition (n = 131)
Number of subjects: 264
Study 19321023 — intervention group
Group type: EXPERIMENTAL
Intervention: Private firm introduction consent form
Number of subjects: 0
Study 19321023 — intervention group
Group type: COMPARATOR
Intervention: Shortened academic ethics committee consent form
Number of subjects: 0
Study 16280255 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir GIQ (genotypic inhibitory quotient) calculated as the ratio between mean trough concentration and number of protease mutations
Number of subjects: 109
Study 15330822 — intervention group
Group type: EXPERIMENTAL
Intervention: Local chilling and topical anti-inflammatory gel
Number of subjects: 0
Study 15330822 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral chilling
Number of subjects: 0
Study 15330822 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of a nonsteroidal anti-inflammatory drug
Number of subjects: 0
Study 11483805 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiant warmer
Number of subjects: 60
Study 11483805 — intervention group
Group type: COMPARATOR
Intervention: Incubator
Number of subjects: 60
Study 9769395 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A: IFO 2.2 g/m2 i.v. as a 4 h infusion on days 1-5, Mesna 600 mg i.v. as push injection at 0 h, 4 h, 8 h on days 1-5, CDDP 20 mg i.v. as a 60 min infusion on days 1-5, repeated every 28 days for 2 cycles.
Number of subjects: 28
Study 9769395 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm B: IFO 1.5 g/m2 i.v. as a 4 h infusion on days 1-5, Mesna 600 mg i.v. as push injection at 0 h, 4 h, 8 h on days 1-5, CDDP 20 mg i.v. as a 60 min infusion on days 1-5, repeated every 28 days for 3 cycles.
Number of subjects: 28
Study 7918930 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumecinol 600 mg once weekly for 3 weeks
Number of subjects: 50
Study 7918930 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumecinol 300 mg daily for 3 weeks
Number of subjects: 50
Study 7918930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 3404165 — intervention group
Group type: EXPERIMENTAL
Intervention: IV glucose
Number of subjects: 8
Study 3404165 — intervention group
Group type: COMPARATOR
Intervention: IV saline
Number of subjects: 8
Study 8460757 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% with adrenaline (15 ml) administered by lumbar epidural injection 15 min before surgery (group A)
Number of subjects: 36
Study 8460757 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.5% with adrenaline (15 ml) administered at the end of surgery (group B)
Number of subjects: 36
Study 675848 — intervention group
Group type: EXPERIMENTAL
Intervention: RCK (Hoffman La Roche, Switzerland)
Number of subjects: 212
Study 675848 — intervention group
Group type: EXPERIMENTAL
Intervention: SCK (BY Sorin‐IRE, Italy)
Number of subjects: 212
Study 675848 — intervention group
Group type: EXPERIMENTAL
Intervention: ICK (Istituto Sieroterapico Milanese, Italy)
Number of subjects: 212
Study 31855055 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural polyphenolic extract from French maritime pine bark, Pycnogenol (PYC)
Number of subjects: 53
Study 31855055 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 28244292 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated, humidified high-flow nasal cannula (HHFNC)
Number of subjects: 85
Study 28244292 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (nCPAP)
Number of subjects: 85
Study 24928286 — intervention group
Group type: COMPARATOR
Intervention: Intravenous diazepam (DZP‐IV)
Number of subjects: 32
Study 24928286 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam (MDZ‐IM)
Number of subjects: 32
Study 24145678 — intervention group
Group type: EXPERIMENTAL
Intervention: IV iron isomaltoside 1,000 (225 patients)
Number of subjects: 338
Study 24145678 — intervention group
Group type: COMPARATOR
Intervention: Oral iron sulfate (113 patients)
Number of subjects: 338
Study 21781344 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based intervention (2011-2012)
Number of subjects: 0
Study 21781344 — intervention group
Group type: COMPARATOR
Intervention: Control arm (receive the intervention after the final follow-up assessment, 2013-2014)
Number of subjects: 0
Study 21781344 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 0
Study 17935921 — intervention group
Group type: EXPERIMENTAL
Intervention: Transarterial infusion (TAI) with water-in-oil-in-water (W/O/W) emulsion containing epirubicin
Number of subjects: 18
Study 17692105 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg
Number of subjects: 24
Study 17692105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 13129812 — intervention group
Group type: EXPERIMENTAL
Intervention: LY354740
Number of subjects: 0
Study 10898131 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg b.i.d.
Number of subjects: 465
Study 10898131 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin 200 mg b.i.d.
Number of subjects: 465
Study 8996854 — intervention group
Group type: EXPERIMENTAL
Intervention: Voltaren (100 mg tablets)
Number of subjects: 20
Study 8996854 — intervention group
Group type: COMPARATOR
Intervention: Inflaban (100 mg enteric-coated tablets)
Number of subjects: 20
Study 8996854 — intervention group
Group type: EXPERIMENTAL
Intervention: Voltaren
Number of subjects: 20
Study 8996854 — intervention group
Group type: COMPARATOR
Intervention: Inflaban
Number of subjects: 20
Study 1362250 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Angiography (MRA) for nonvascular pathology (n = 42)
Number of subjects: 150
Study 1362250 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Angiography (MRA) for vascular lesions (n = 108)
Number of subjects: 150
Study 6364906 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg terbutaline sulfate
Number of subjects: 7
Study 6364906 — intervention group
Group type: COMPARATOR
Intervention: 0.25 ml normal saline solution (placebo)
Number of subjects: 7
Study 31262366 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cells (MSCs) embedded in a xenogenic scaffold
Number of subjects: 13
Study 31262366 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 13
Study 27943112 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 147
Study 27943112 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 147
Study 25528281 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly maintenance Cognitive Stimulation Therapy (CST) added to usual care for 24 weeks
Number of subjects: 236
Study 25528281 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone for 24 weeks
Number of subjects: 236
Study 25528281 — intervention group
Group type: EXPERIMENTAL
Intervention: CST in combination with acetylcholinesterase inhibitors (ACHEIs)
Number of subjects: 236
Study 23624802 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated interferon alpha‐2b (PEG‐IFNα‐2b) therapy
Number of subjects: 91
Study 23624802 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 91
Study 23624802 — intervention group
Group type: EXPERIMENTAL
Intervention: SOCS1 and SOCS3 mRNA levels
Number of subjects: 91
Study 21285885 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (1200 mg/day)
Number of subjects: 70
Study 21285885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 19342599 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term fasting
Number of subjects: 0
Study 19342599 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic caloric restriction
Number of subjects: 0
Study 19342599 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise
Number of subjects: 0
Study 19342599 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid injection
Number of subjects: 0
Study 19342599 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenergic agonist treatment
Number of subjects: 0
Study 19342599 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty acids
Number of subjects: 0
Study 17356056 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled mometasone 400 microg once daily for 8 weeks
Number of subjects: 33
Study 17356056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 15036740 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral pulse assessment
Number of subjects: 0
Study 15036740 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachial pulse assessment
Number of subjects: 0
Study 15036740 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord palpation
Number of subjects: 0
Study 15036740 — intervention group
Group type: EXPERIMENTAL
Intervention: Stethoscope assessment
Number of subjects: 0
Study 11419379 — intervention group
Group type: EXPERIMENTAL
Intervention: Public condition (participants shared their answers and confidence ratings aloud)
Number of subjects: 96
Study 11419379 — intervention group
Group type: COMPARATOR
Intervention: Private condition (participants did not share their answers and ratings)
Number of subjects: 96
Study 9189782 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose ingested during exercise
Number of subjects: 6
Study 9189782 — intervention group
Group type: COMPARATOR
Intervention: Placebo ingested during exercise
Number of subjects: 6
Study 8349988 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant grip force of 11.3 kg (Group I)
Number of subjects: 66
Study 8349988 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum grip effort resulting in a mean grip force of 30 kg (Group II)
Number of subjects: 66
Study 3775265 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacitracin
Number of subjects: 7
Study 3775265 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 7
Study 3775265 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 7
Study 3775265 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazol
Number of subjects: 7
Study 3775265 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 7
Study 3775265 — intervention group
Group type: COMPARATOR
Intervention: Nalidixic acid
Number of subjects: 7
Study 3775265 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin
Number of subjects: 7
Study 30779431 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher DDP countries
Number of subjects: 18627
Study 30779431 — intervention group
Group type: COMPARATOR
Intervention: Higher restrictive alcohol policy
Number of subjects: 18627
Study 28958052 — intervention group
Group type: EXPERIMENTAL
Intervention: AutoEPAP
Number of subjects: 25
Study 28958052 — intervention group
Group type: COMPARATOR
Intervention: FixedEPAP
Number of subjects: 25
Study 28958052 — intervention group
Group type: EXPERIMENTAL
Intervention: AutoEPAP and FixedEPAP
Number of subjects: 25
Study 24638207 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic lozenges containing Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp. lactis BB-12 (4 weeks)
Number of subjects: 60
Study 24638207 — intervention group
Group type: COMPARATOR
Intervention: Lozenges without added probiotics (control group)
Number of subjects: 60
Study 23817872 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 (3 g, Lovaza, GSK)
Number of subjects: 85
Study 23817872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 23817872 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3
Number of subjects: 85
Study 21574963 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 130/0.42/6:1 (Venofundin(®))
Number of subjects: 84
Study 21574963 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 130/0.4/9:1 (Voluven(®))
Number of subjects: 84
Study 21574963 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 200/0.5/5:1 (Haes‐steril(®))
Number of subjects: 84
Study 21574963 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% dextran 70 (Macrodex(®))
Number of subjects: 84
Study 21574963 — intervention group
Group type: EXPERIMENTAL
Intervention: All colloids
Number of subjects: 84
Study 19689920 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine
Number of subjects: 339
Study 19689920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 339
Study 19689920 — intervention group
Group type: COMPARATOR
Intervention: Agomelatine and Placebo
Number of subjects: 339
Study 16965560 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for intervention clinicians (2 hours total, including a booster session and study materials)
Number of subjects: 164
Study 16965560 — intervention group
Group type: COMPARATOR
Intervention: Usual care by control clinicians
Number of subjects: 164
Study 16965560 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for intervention clinicians
Number of subjects: 164
Study 15286541 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy plus extracorporeal endotoxin adsorption
Number of subjects: 145
Study 15286541 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy alone for sepsis
Number of subjects: 145
Study 11140431 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 500 microg administered twice daily via Diskhaler for 6 weeks
Number of subjects: 0
Study 11140431 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 500 microg administered via Diskus or Diskhaler for 12 weeks
Number of subjects: 0
Study 11140431 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) via either DPI
Number of subjects: 0
Study 9338545 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal challenge with ragweed antigen extract
Number of subjects: 0
Study 9338545 — intervention group
Group type: COMPARATOR
Intervention: Intranasal beclomethasone before challenge
Number of subjects: 0
Study 7701795 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic lymphadenectomy
Number of subjects: 67
Study 7701795 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylactic lymphadenectomy)
Number of subjects: 67
Study 3664426 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) 10 mg to 20 mg twice orally
Number of subjects: 127
Study 3664426 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (NAN) 50 mg every second week or 100 mg every third week intramuscularly
Number of subjects: 127
Study 3664426 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (TAM)
Number of subjects: 127
Study 3664426 — intervention group
Group type: COMPARATOR
Intervention: Nandrolone decanoate (NAN)
Number of subjects: 127
Study 3664426 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (NAN) after Tamoxifen (TAM)
Number of subjects: 127
Study 3664426 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (TAM) after Nandrolone decanoate (NAN)
Number of subjects: 127
Study 29220121 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 kHz spinal cord stimulation (SCS)
Number of subjects: 0
Study 29220121 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 kHz spinal cord stimulation (SCS)
Number of subjects: 0
Study 29220121 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 kHz spinal cord stimulation (SCS)
Number of subjects: 0
Study 29220121 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 kHz spinal cord stimulation (SCS)
Number of subjects: 0
Study 28303726 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet injection of insulin aspart (0.2 units/kg body weight)
Number of subjects: 30
Study 28303726 — intervention group
Group type: COMPARATOR
Intervention: Conventional pen administration of insulin aspart (0.2 units/kg body weight)
Number of subjects: 30
Study 28303726 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet injection of insulin aspart
Number of subjects: 30
Study 28303726 — intervention group
Group type: COMPARATOR
Intervention: Conventional pen administration of insulin aspart
Number of subjects: 30
Study 26208795 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg/day
Number of subjects: 51
Study 26208795 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 51
Study 22695016 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided surgical simulation (CASS) protocol with chin template
Number of subjects: 65
Study 22695016 — intervention group
Group type: COMPARATOR
Intervention: Computer-aided surgical simulation (CASS) protocol without chin template
Number of subjects: 65
Study 22695016 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided surgical simulation (CASS) protocol
Number of subjects: 65
Study 21946803 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered collaborative care intervention
Number of subjects: 150
Study 21946803 — intervention group
Group type: EXPERIMENTAL
Intervention: Components of collaborative care
Number of subjects: 150
Study 18781134 — intervention group
Group type: EXPERIMENTAL
Intervention: Vindesine treatment for 2 years
Number of subjects: 142
Study 18781134 — intervention group
Group type: COMPARATOR
Intervention: Observation alone
Number of subjects: 142
Study 18781134 — intervention group
Group type: EXPERIMENTAL
Intervention: Vindesine treatment
Number of subjects: 142
Study 16958010 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual endoscopy (VE) simulation
Number of subjects: 13
Study 12944243 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone 50 microg/kg plus 0.5 microg/kg/min for 10 hours
Number of subjects: 45
Study 12944243 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone 1.5 mg/kg plus 10 microg/kg/min infusion for 10 hours
Number of subjects: 45
Study 12944243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 12944243 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 45
Study 12944243 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone
Number of subjects: 45
Study 10651749 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment
Number of subjects: 13
Study 10651749 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 13
Study 7495244 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene 50 mg/d and retinol 25,000 IU/d on alternate days
Number of subjects: 755
Study 7495244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 755
Study 2183940 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime with metronidazole
Number of subjects: 100
Study 2183940 — intervention group
Group type: COMPARATOR
Intervention: Netilmicin with metronidazole
Number of subjects: 100
Study 536838 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc‐99m antimony sulfide
Number of subjects: 46
Study 536838 — intervention group
Group type: COMPARATOR
Intervention: Tc‐99m stannous phytate
Number of subjects: 46
Study 30938681 — intervention group
Group type: EXPERIMENTAL
Intervention: SmartLink app (intervention arm)
Number of subjects: 345
Study 30938681 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control arm)
Number of subjects: 345